

PRODUCT INFORMATION



Udenafil

Item No. 30373

CAS Registry No.: 268203-93-6
Formal Name: 3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-N-[2-(1-methyl-2-pyrrolidiny)ethyl]-4-propoxy-benzenesulfonamide

Synonym: DA-8159

MF: C₂₅H₃₆N₆O₄S

FW: 516.7


Purity: ≥95%

UV/Vis.: λ_{max}: 285 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Udenafil is supplied as a crystalline solid. A stock solution may be made by dissolving the udenafil in the solvent of choice, which should be purged with an inert gas. Udenafil is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of udenafil in ethanol is approximately 1 mg/ml and approximately 30 mg/ml in DMSO and DMF.

Udenafil is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, udenafil should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Udenafil has a solubility of approximately 0.2 mg/ml in a 1:4 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Udenafil is an inhibitor of phosphodiesterase 5 (PDE5).¹⁻³ *In vivo*, udenafil (1 and 5 mg/kg) increases lung cGMP levels, attenuates the development of compensatory right ventricular hypertrophy, and reduces pulmonary arterial wall thickening in a rat model of monocrotaline-induced pulmonary hypertension.¹ It increases creatine clearance and decreases blood urea nitrogen (BUN) and serum malondialdehyde (MDA) levels in a rat model of renal ischemia-reperfusion injury.² Udenafil (0.3 and 10 mg/kg) induces penile erections in conscious rabbits and in rabbits with acute spinal cord injury.³

References

1. Kang, K.K., Ahn, G.J., Sohn, Y.S., *et al.* DA-8159, a new PDE5 inhibitor, attenuates the development of compensatory right ventricular hypertrophy in a rat model of pulmonary hypertension. *J. Int. Med. Res.* **31(6)**, 517-528 (2003).
2. Özlülerden, Y., Toktaş, C., Aybek, H., *et al.* The renoprotective effects of mannitol and udenafil in renal ischemia-reperfusion injury model. *Invest. Clin. Urol.* **58(4)**, 289-295 (2017).
3. Kang, K.K., Ahn, G.J., Ahn, B.O., *et al.* DA-8159, a new PDE5 inhibitor, induces penile erection in conscious and acute spinal cord injured rabbits. *Eur. Urol.* **43(6)**, 689-695 (2003).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 05/28/2020

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM